Brooklyn ImmunoTherapeutics Inc. (BTX): Price and Financial Metrics
BTX Price/Volume Stats
| Current price | $4.10 | 52-week high | $10.10 |
| Prev. close | $0.21 | 52-week low | $0.17 |
| Day low | $3.62 | Volume | 127,880 |
| Day high | $4.20 | Avg. volume | 515,543 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $1.28 | Market Cap | 241.30M |
BTX Stock Price Chart Interactive Chart >
Brooklyn ImmunoTherapeutics Inc. (BTX) Company Bio
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.
BTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -95.79% |
| 5-year | -95.76% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -6.92% |
| 2020 | 1.82% |
| 2019 | 12.82% |
Loading social stream, please wait...